Armin Rashidi, MD, PhD

Dr. Armin Rashidi studies how the microbiome, the community of bacteria living in and on our bodies, influences patients’ outcomes after intensive therapy for blood cancers. Our health is intimately tied to the health of our microbiomes, and treatment regimens for blood cancers, which can include immune-suppressing chemotherapy and antibiotics to stave off infection, often disrupt these communities. This disruption, or dysbiosis, can open the door to life-threatening infections and influence treatment complications. Rashidi studies how the makeup of individual microbiomes influence how they respond to cancer treatments and how different blood cancer treatments alter the patients’ microbiomes. With these insights, Rashidi hopes to develop better strategies to prevent and treat dysbiosis and improve blood cancer treatment outcomes.